CL2011002675A1 - Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende. - Google Patents

Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.

Info

Publication number
CL2011002675A1
CL2011002675A1 CL2011002675A CL2011002675A CL2011002675A1 CL 2011002675 A1 CL2011002675 A1 CL 2011002675A1 CL 2011002675 A CL2011002675 A CL 2011002675A CL 2011002675 A CL2011002675 A CL 2011002675A CL 2011002675 A1 CL2011002675 A1 CL 2011002675A1
Authority
CL
Chile
Prior art keywords
compounds
ophthalmic
dihydroxytetrahydrofuran
purin
pharmaceutical composition
Prior art date
Application number
CL2011002675A
Other languages
English (en)
Spanish (es)
Inventor
Shikha Baumgarter Rodulf A Barman
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43030847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011002675(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of CL2011002675A1 publication Critical patent/CL2011002675A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Prostheses (AREA)
CL2011002675A 2009-05-01 2011-10-27 Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende. CL2011002675A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17465509P 2009-05-01 2009-05-01
US21999009P 2009-06-24 2009-06-24

Publications (1)

Publication Number Publication Date
CL2011002675A1 true CL2011002675A1 (es) 2012-06-01

Family

ID=43030847

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002675A CL2011002675A1 (es) 2009-05-01 2011-10-27 Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.

Country Status (25)

Country Link
US (2) US8470800B2 (https=)
EP (1) EP2424546B1 (https=)
JP (1) JP5778663B2 (https=)
KR (1) KR101757940B1 (https=)
CN (1) CN102413832B (https=)
AU (1) AU2010242943B2 (https=)
BR (1) BRPI1009971A2 (https=)
CA (1) CA2762064A1 (https=)
CL (1) CL2011002675A1 (https=)
DK (1) DK2424546T3 (https=)
EA (1) EA024042B1 (https=)
ES (1) ES2554684T3 (https=)
HR (1) HRP20151200T1 (https=)
HU (1) HUE028068T2 (https=)
IL (1) IL216081A (https=)
MX (1) MX2011011229A (https=)
MY (1) MY159244A (https=)
NZ (1) NZ596428A (https=)
PL (1) PL2424546T3 (https=)
PT (1) PT2424546E (https=)
RS (1) RS54378B1 (https=)
SG (1) SG175346A1 (https=)
SI (1) SI2424546T1 (https=)
SM (1) SMT201500295B (https=)
WO (1) WO2010127210A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008062567A1 (de) 2008-12-16 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Dipeptoid-Prodrugs und ihre Verwendung
DE102009006602A1 (de) * 2009-01-29 2010-08-05 Bayer Schering Pharma Aktiengesellschaft Alkylamino-substituierte Dicyanopyridine und deren Aminosäureester-Prodrugs
CA2774704A1 (en) * 2009-10-26 2011-05-05 Inotek Pharmaceuticals Corporation Ophthalmic formulation and method of manufacture thereof
SG182285A1 (en) * 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
PT2555775T (pt) * 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e inibidores de anidrase carbónica para redução da pressão intra-ocular
ES2613255T3 (es) * 2010-03-19 2017-05-23 Inotek Pharmaceuticals Corporation Composiciones combinadas de agonistas de adenosina A1 y bloqueadores de receptores ß-adrenérgicos no selectivos para reducir la presión intraocular
EA201290958A1 (ru) 2010-03-26 2013-04-30 Инотек Фармасьютикалз Корпорейшн Способ снижения внутриглазного давления у людей с применением n6-циклопентиладенозина (cpa), производных cpa или их пролекарств
DE102010030688A1 (de) 2010-06-30 2012-01-05 Bayer Schering Pharma Aktiengesellschaft Substituierte Dicyanopyridine und ihre Verwendung
US20120058983A1 (en) 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
BR112014018413A8 (pt) * 2012-01-26 2017-07-11 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de metila [(2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-diidroxitetraidrofuran-2-il)] e processos de preparação do mesmo
CA2903114A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
JP2018501219A (ja) * 2014-12-03 2018-01-18 イノテック ファーマシューティカルズ コーポレイション 黄斑変性の予防、軽減または治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005117910A2 (en) * 2004-05-26 2005-12-15 Inotek Pharmaceuticals Corporation Purine derivatives as adenosine a1 receptor agonists and methods of use thereof
CN101010085B (zh) 2004-05-26 2012-12-26 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
EA015683B1 (ru) * 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
CA2774704A1 (en) * 2009-10-26 2011-05-05 Inotek Pharmaceuticals Corporation Ophthalmic formulation and method of manufacture thereof
SG182285A1 (en) * 2010-01-11 2012-08-30 Inotek Pharmaceuticals Corp Combination, kit and method of reducing intraocular pressure
PT2555775T (pt) * 2010-03-19 2017-02-01 Inotek Pharmaceuticals Corp Composições de combinação de agonistas de adenosina a1 e inibidores de anidrase carbónica para redução da pressão intra-ocular
ES2613255T3 (es) * 2010-03-19 2017-05-23 Inotek Pharmaceuticals Corporation Composiciones combinadas de agonistas de adenosina A1 y bloqueadores de receptores ß-adrenérgicos no selectivos para reducir la presión intraocular

Also Published As

Publication number Publication date
EA201171339A1 (ru) 2012-05-30
SG175346A1 (en) 2011-11-28
AU2010242943A1 (en) 2011-12-01
DK2424546T3 (en) 2015-12-14
JP5778663B2 (ja) 2015-09-16
US20100279970A1 (en) 2010-11-04
US8470800B2 (en) 2013-06-25
RS54378B1 (sr) 2016-04-28
EP2424546A1 (en) 2012-03-07
WO2010127210A1 (en) 2010-11-04
EA024042B1 (ru) 2016-08-31
EP2424546B1 (en) 2015-10-28
IL216081A (en) 2015-11-30
HRP20151200T1 (hr) 2016-01-15
IL216081A0 (en) 2012-01-31
SMT201500295B (it) 2016-01-08
HUE028068T2 (en) 2016-11-28
CN102413832A (zh) 2012-04-11
MY159244A (en) 2016-12-30
HK1167599A1 (en) 2012-12-07
PT2424546E (pt) 2015-12-23
CN102413832B (zh) 2015-11-25
SI2424546T1 (sl) 2016-02-29
ES2554684T3 (es) 2015-12-22
BRPI1009971A2 (pt) 2016-03-15
EP2424546A4 (en) 2013-01-23
CA2762064A1 (en) 2010-11-04
MX2011011229A (es) 2011-11-18
PL2424546T3 (pl) 2016-04-29
KR20120017026A (ko) 2012-02-27
NZ596428A (en) 2014-03-28
JP2012525437A (ja) 2012-10-22
KR101757940B1 (ko) 2017-07-13
AU2010242943B2 (en) 2016-09-29
US20130217643A1 (en) 2013-08-22

Similar Documents

Publication Publication Date Title
CL2011002675A1 (es) Uso de compuestos derivados de nitrato o sulfato de 9-purin-9-il-3,4-dihidroxitetrahidrofuran-2-il-metilo para reducir la presion intraocular ; composicion farmaceutica oftalmica que comprende los compuestos; y formulacion oftalmica de uso topico que los comprende.
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
MX345697B (es) Formulaciones de rifaximina y usos de las mismas.
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
MX338712B (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
UY31673A1 (es) "derivados heterocíclicos de urea y métodos de uso de los mismos-211"
MX353827B (es) Formas de rifaximina y usos de la misma.
SV2010003559A (es) Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
AR047928A1 (es) Derivados de tetrahidropiridoindol
CL2014001158A1 (es) Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros.
CL2012003075A1 (es) Composicion farmaceutica en solucion de pazopanib, estable y para uso oftalmico; metodo para la preparacion de dicha solucion.
BRPI1106572B8 (pt) Composições que compreendem um retinoide e um inibidor de nfkb e seus métodos de uso
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2008001323A1 (es) Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
UY34008A (es) ?formas en estado sólido de inhibidor de hiv, composición farmacéutica, uso de la misma, y procesos para preparar dichas formas?.
UY30215A1 (es) Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones
CL2008002185A1 (es) Compuestos derivados de pirimidina, inhibidores de fosfatidilinositol-3-cinasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de enfermedades resapiratorias, alergias, inflamacion, cancer, entre otras enfermedades.
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora